Skip to main content
. 2019 Dec 12;138(2):136–146. doi: 10.1001/jamaophthalmol.2019.5132

Figure. Kaplan-Meier Analysis for Poor Visual Acuity Outcome (≤20/200) After Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab for Uveal Melanoma.

Figure.

Comparison of patients treated with prophylactic intravitreal bevacizumab at 4-month intervals for a duration of 2 years vs control individuals treated with observation alone revealed no difference in Kaplan-Meier–estimated poor visual outcome (61% vs 61%; hazard ratio, 1.26; 95% CI, 0.95-1.69; P = .11) at 4 years.